JP2006526412A - イリノテカン毒性を推定する方法および組成物 - Google Patents

イリノテカン毒性を推定する方法および組成物 Download PDF

Info

Publication number
JP2006526412A
JP2006526412A JP2006515008A JP2006515008A JP2006526412A JP 2006526412 A JP2006526412 A JP 2006526412A JP 2006515008 A JP2006515008 A JP 2006515008A JP 2006515008 A JP2006515008 A JP 2006515008A JP 2006526412 A JP2006526412 A JP 2006526412A
Authority
JP
Japan
Prior art keywords
ugt1a1
irinotecan
patient
nucleic acid
genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006515008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526412A5 (enExample
Inventor
マーク ジェイ． ラテイン
フェデリコ イノチェンティ
アンナ ディリエンツォ
キャリー グレムスリー
Original Assignee
ユニバーシティ オブ シカゴ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ シカゴ filed Critical ユニバーシティ オブ シカゴ
Publication of JP2006526412A publication Critical patent/JP2006526412A/ja
Publication of JP2006526412A5 publication Critical patent/JP2006526412A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2006515008A 2003-05-30 2004-05-28 イリノテカン毒性を推定する方法および組成物 Pending JP2006526412A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47482603P 2003-05-30 2003-05-30
PCT/US2004/016920 WO2004108954A1 (en) 2003-05-30 2004-05-28 Methods and compositions for predicting irinotecan toxicity

Publications (2)

Publication Number Publication Date
JP2006526412A true JP2006526412A (ja) 2006-11-24
JP2006526412A5 JP2006526412A5 (enExample) 2007-02-08

Family

ID=33511633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006515008A Pending JP2006526412A (ja) 2003-05-30 2004-05-28 イリノテカン毒性を推定する方法および組成物

Country Status (8)

Country Link
US (1) US7807350B2 (enExample)
EP (1) EP1629111B1 (enExample)
JP (1) JP2006526412A (enExample)
AT (1) ATE397091T1 (enExample)
CA (1) CA2527320A1 (enExample)
DE (1) DE602004014135D1 (enExample)
ES (1) ES2308208T3 (enExample)
WO (1) WO2004108954A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066136A1 (fr) * 2006-11-30 2008-06-05 Arkray, Inc. Ensemble d'amorces pour l'amplification du gène ugt1a1, réactif pour l'amplification du gène ugt1a1 comprenant cet ensemble d'amorces, et utilisation de cet ensemble d'amorces

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055261A1 (ja) * 2005-11-10 2007-05-18 The New Industry Research Organization Ｕｇｔ１ａ１遺伝子多型の検査法
CN107858429A (zh) * 2017-11-10 2018-03-30 广州金域医学检验集团股份有限公司 用于检测ugt1a1基因启动子区ta重复多态性的扩增引物、方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5972614A (en) * 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
DE69734237T2 (de) 1996-03-01 2006-07-06 The University Court Of The University Of Dundee, Dundee Versuchsystem für einen Arzneimittelversuch
US6287834B1 (en) * 1996-05-17 2001-09-11 Endorecherche, Inc. Characterization and use of an isolated uridine diphospho-glucuronosyltransferase
DE19744676A1 (de) 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
WO1999057322A2 (en) 1998-05-07 1999-11-11 Axys Pharmaceuticals, Inc. Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
US6448003B1 (en) * 1998-06-10 2002-09-10 Dna Sciences Laboratories, Inc. Genotyping the human phenol sulfotransferbase 2 gene STP2
US6407117B1 (en) * 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
US6319678B1 (en) * 1998-06-26 2001-11-20 Panvera Corporation Process for glucuronidation screening
US6586175B1 (en) * 1998-07-28 2003-07-01 Dna Sciences Laboratories, Inc. Genotyping the human UDP-glucuronosyltransferase 2B7 (UGT2B7) gene
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
AU2001255397A1 (en) 2000-04-18 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the ugt1a1 gene
EP1325152A2 (en) 2000-07-14 2003-07-09 F. Hoffmann-La Roche Ag Method for detecting pre-disposition to hepatotoxicity
AU2002245039A1 (en) 2000-11-28 2002-07-30 Dna Sciences Laboratories, Inc. Genetic typing of human genes and related materials and methods
EP1352970B1 (en) 2000-12-12 2010-06-02 Nagoya Industrial Science Research Institute Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabloized per se by ugt1a1 or whose intermediate is metabolized by the enzyme
DE10100238A1 (de) * 2001-01-05 2002-08-22 Hannover Med Hochschule Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests
WO2002059375A2 (en) * 2001-01-26 2002-08-01 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
WO2003013534A2 (en) 2001-07-23 2003-02-20 Epidauros Biotechnologie Ag Methods for the treatment of cancer with irinotecan based on cyp3a5
JP4096037B2 (ja) 2002-08-12 2008-06-04 国立大学法人滋賀医科大学 グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法
US20040203034A1 (en) * 2003-01-03 2004-10-14 The University Of Chicago Optimization of cancer treatment with irinotecan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010016821, Ｃａｎｃｅｒ Ｒｅｓ． （１９９４） ｖｏｌ．５４， ｎｏ．１４， ｐ．３７２３−３７２５ *
JPN6010016823, Ｐｈａｒｍａｃｏｇｅｎｅｔｉｃｓ （２００２） ｖｏｌ．１２， ｎｏ．９， ｐ．７２５−７３３ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066136A1 (fr) * 2006-11-30 2008-06-05 Arkray, Inc. Ensemble d'amorces pour l'amplification du gène ugt1a1, réactif pour l'amplification du gène ugt1a1 comprenant cet ensemble d'amorces, et utilisation de cet ensemble d'amorces
EP2463365A1 (en) * 2006-11-30 2012-06-13 ARKRAY, Inc. Probes for detection of UGT1A1 gene, reagent for detection of UGT1A1 gene comprising the same, and uses thereof
US8357516B2 (en) 2006-11-30 2013-01-22 Arkray, Inc. Primer set for amplification of UGT1A1 gene, reagent for amplification of UGT1A1 gene containing the same, and the uses thereof
US9175272B2 (en) 2006-11-30 2015-11-03 Arkray, Inc. Probes for detection of UGT1A1 gene, reagent containing the same, and the uses thereof

Also Published As

Publication number Publication date
EP1629111A1 (en) 2006-03-01
CA2527320A1 (en) 2004-12-16
ES2308208T3 (es) 2008-12-01
EP1629111B1 (en) 2008-05-28
DE602004014135D1 (de) 2008-07-10
WO2004108954A1 (en) 2004-12-16
ATE397091T1 (de) 2008-06-15
US20070197574A1 (en) 2007-08-23
US7807350B2 (en) 2010-10-05

Similar Documents

Publication Publication Date Title
AU2016204678B2 (en) Method of identifying disease risk factors
US7879551B2 (en) Methods and materials for identifying polymorphic variants, diagnosing susceptibilities, and treating disease
US20040203034A1 (en) Optimization of cancer treatment with irinotecan
US20090325156A1 (en) Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
US20090017452A1 (en) Methods and compositions relating to the pharmacogenetics of different gene variants
US20090176878A1 (en) Genetic polymorphisms and substance dependence
JP2007527241A (ja) 上皮細胞成長因子受容体遺伝子プロモーターにおける多型
US7807350B2 (en) Methods for predicting irinotecan toxicity
WO2008128233A1 (en) Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)
KR102443042B1 (ko) 직접경구용 항응고제 투여시의 출혈 부작용 예측용 snp 마커 및 이의 용도
US20090247475A1 (en) Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
WO2006124646A2 (en) Methods and compostions relating to the pharmacogenetics of different gene variants in the context of irinotecan-based therapies
US7935485B2 (en) Genetic polymorphisms for identifying individuals at risk for drug-induced vestibular dysfunction
AU2014335747A1 (en) Genotyping tests and methods for evaluating plasma creatine kinase levels
US20110143344A1 (en) Genetic polymorphisms and substance dependence
JP2007517511A (ja) ヒトチオプリンｓ−メチルトランスフェラーゼ欠損に関連するハプロタイプおよび多型
CA2501253A1 (en) Means and methods for individualized drug therapy and for predicting adverse drug reaction
AU2013202634B2 (en) Method of identifying disease risk factors
WO2009046118A1 (en) Cancer susceptibility loci located at chromosome 6p22 and chromosome 20 for use in diagnostic and therapeutic methods
WO2006084133A2 (en) Methods for dosing l-thyroxine
KR20050018500A (ko) 동양인의 ｃｆｔｒ 유전자 변이에 의해서 유발되는 만성호흡기 및 췌장 질환 진단용 키트
HK1153511B (en) Method of identifying alzheimer's disease risk factors
WO2003074729A1 (en) Method for diagnosing and treating predisposition for accelerated autosomal dominant polycystic kidney disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100628

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101122